SCHEMBL6101980

SCHEMBL6101980

CCc1ccc(NC(=O)c2cc(N3CCCC(O)C3)nc3ccccc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.55
HIF1A Q16665 3/20 0.55
ALDH1A1 P00352 6/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 2/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
MAPT P10636 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
RCE1 Q9Y256 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 2/20 0.45
TP53 P04637 1/20 0.45
ACACB O00763 1/20 0.45
ACACA Q13085 1/20 0.45
MCHR1 Q99705 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100437 0.94 KDM4E (0.56) KDM4EHIF1AALDH1A1MEN1KMT2A
Ethane SCHEMBL6101984 0.91 KDM4E (0.62) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6111961 0.89 KDM4E (0.53) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6097470 0.89 KDM4E (0.65) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6097763 0.88 KDM4E (0.64) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6099924 0.88 KDM4E (0.64) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6097646 0.85 KDM4E (0.61) KDM4EHIF1AALDH1A1MEN1KMT2A
Ethane SCHEMBL6100439 0.85 KDM4E (0.65) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6100965 0.83 KDM4E (0.56) KDM4EHIF1AALDH1A1MEN1KMT2A
SCHEMBL6102421 0.83 KDM4E (0.64) KDM4EHIF1AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020156095-A1 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION 2002-10-24 US claimed
US-7041664-B2 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION (US) 2006-05-09 US disclosed
US-6894044-B2 2-aminoquinolinecarboxamides: neurokinin receptor ligands NEUROGEN CORPORATION (US) 2005-05-17 US disclosed
US-6369053-B1 CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES; ALSO USEFUL AS PROBES FOR THE LOCALIZATION OF CELL SURFACE RECEPTORS; NONPEPTIDE NK-3 RECEPTOR ANTAGONISTS NEUROGEN CORPORATION 2002-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156095-A1 2-aminoquinolinecarboxamides: neurokinin receptor ligands KCNQ3, OPRK1, KCNQ1 KDM4E 2712/4885HIF1A 3061/4885ALDH1A1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.